

~~Please cancel claims 120 and 121, without prejudice.~~

Please amend the following claim:

115. (Once amended) An isolated polynucleotide comprising a nucleic acid selected from the group consisting of:

(a) [a nucleic acid encoding amino acids +30 to +44 of SEQ ID NO:2;

(b) a nucleic acid encoding amino acids +55 to +69 of SEQ ID NO:2;

(c)] a nucleic acid encoding a polypeptide fragment of SEQ ID NO:2 or a polypeptide fragment encoded by the cDNA contained in ATCC Deposit No. 75874, wherein the polypeptide fragment binds an antibody having specificity for the polypeptide of SEQ ID NO:2;

g1 [(d)](b) a nucleic acid that hybridizes to a polynucleotide consisting of SEQ ID NO:1, the complement thereof, or the cDNA contained in ATCC Deposit No. 75874 under hybridization conditions comprising hybridization in a wash buffer consisting of 0.2XSSC and 0.1% SDS at 60°C;

[(e)](c) a nucleic acid sequence comprising 30 contiguous nucleotides of SEQ ID NO:1 or the complement thereof; and

[(f)](d) a nucleic acid sequence comprising 50 contiguous nucleotides of SEQ ID NO:1 or the complement thereof.

Remarks

Claims 54-67, 75-92, 102-107, 115-119, and 122-175 are pending in the current application. Claim 115 has been amended and claims 120 and 121 have been cancelled to more particularly point out and distinctly claim the subject matter Applicants view as the invention. The specification has been amended to reflect the claim to priority. No new matter has been added by way of the amendments to the claims or the specification.

Formal drawings of Figures 1A-1E and 2 have been submitted for entry in the instant application.